CONSOLIDATED STATEMENTS OF (DEFICIT) EQUITY - USD ($)	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]	Total
Balance at Sep. 30, 2018	$ 753	$ 249,119,833	$ (248,366,083)		$ 754,503
Balance (in shares) at Sep. 30, 2018	752,802
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other	$ 8	(8)
Other (in shares)	7,594
Common stock issued in public offering, net of offering costs	$ 150	2,463,441			2,463,591
Common stock issued in public offering, net of offering costs (in shares)	150,000
Common stock issued in private placement, net of offering costs	$ 39	402,342			402,381
Common stock issued in private placement, net of offering costs (in shares)	38,704
Exercise of warrants	$ 55	987,446	0	$ 0	987,501
Exercise of warrants (in shares)	55,376
Exercise of warrants cashlessly	$ 100	(100)
Exercise of warrants cashlessly (in shares)	100,617
Common stock issued in secured convertible note conversion	$ 103	1,440,402			1,440,505
Common stock issued in secured convertible note conversion (in shares)	102,900
Deemed dividend - warrant repricing		309,607	(309,607)
Investment in LineaRx, Inc.		110,849		2,283	113,132
Impact of adoption of new accounting pronouncements included in accumulated deficit			493,224		493,224
Stock based compensation expense		1,129,110			1,129,110
Net loss			(8,623,123)	(9,323)	(8,632,446)
Balance at Sep. 30, 2019	$ 1,208	255,962,922	(256,805,589)	(7,040)	$ (848,499)
Balance (in shares) at Sep. 30, 2019	1,207,993				1,207,993
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued in public offering, net of offering costs	$ (2,285)	(10,527,745)			$ (10,530,030)
Common stock issued in public offering, net of offering costs (in shares)	2,285,000
Exercise of warrants	$ 1,651	8,054,146	0	0	8,055,797
Exercise of warrants (in shares)	1,649,786
Deemed dividend - warrant repricing		2,842	(2,842)
Stock based compensation expense		1,001,082			1,001,082
Net loss			(13,027,219)	(1,685)	(13,028,904)
Balance at Sep. 30, 2020	$ 5,144	$ 275,548,737	$ (269,835,650)	$ (8,725)	$ 5,709,506
Balance (in shares) at Sep. 30, 2020	5,142,779				5,142,779